ImaginAb and [Yantai] DongCheng Pharmaceutical Group Sign Exclusive License Agreement to Commercialize CD8 ImmunoPET Agent in China to Serve Pharma and Healthcare Community

Los Angeles, USA and Yantai, China – May 24th, 2022 – ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce the signing of an exclusive license with [Yantai] DongCheng Pharmaceutical Group to commercialize ImaginAb’s CD8 ImmunoPET agent (zirconium Zr 89 crefmirlimab berdoxam) in the Greater China market. Zirconium Zr 89 crefmirlimab berdoxam will be initially used in third party sponsored clinical trials with the intention of achieving market authorization.

Read more…